caa a22 4500 605490236 CHVBK 20210128100503.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0686-2 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0686-2 Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget's disease [Elektronische Daten] [Yasutaka Tokuda, Fuyuko Arakura, Hisashi Uhara] Background: Extramammary Paget's disease (EPD) is a cutaneous adenocarcinoma. It is usually curable by wide local excision. However, the prognosis for EPD patients with metastases is extremely poor because effective chemotherapy for advanced EPD has not been established. Methods: We retrospectively analyzed the efficacy of combination chemotherapy consisting of infusions of 5-fluorouracil (5-FU, 600mg/m2/body, 5 days/week) and cisplatin (5-10mg/body, 5-7days/week) administered intravenously for 8-24h (low-dose FP). Results: The patients were 15 males and 7 females and the ages ranged from 54 to 91years old (median 71). The toxicities of low-dose FP were as follows: hematopoietic dysfunction (n=4), gastrointestinal dysfunction (4), nephropathy (1), and phlebitis (1). Almost all toxicities were grade 1 or 2 except for 2 cases with grade 3 leukopenia or pancytopenia. Seventeen patients were treated with low-dose FP only, and the clinical results included 10 partial responses (PR), 4 stable disease (SD), and 3 progressive disease (PD). The overall survival ranges (medians) were 5-51months (12) in all 22 patients, 6-51months (13) in the 13 patients showing complete response or PR, and 5-12months (11) in the 6 SD patients. The reported palliative effects of low-dose FP include control of pain and improvement of lymphedema. Conclusion: Although the number of cases is limited and there is a bias because cases without clinical effects are less likely to be reported, this regimen might be considered a relatively effective option for advanced EPD. Japan Society of Clinical Oncology, 2014 Extramammary Paget's disease nationallicence Chemotherapy nationallicence 5-Fluorouracil nationallicence Cisplatin nationallicence Tokuda Yasutaka Division of Dermatology, Matsumoto Medical Center, Minami, 2-20-30, Murai, 399-8701, Matsumoto, Nagano, Japan aut Arakura Fuyuko Division of Dermatology, Matsumoto Medical Center, Minami, 2-20-30, Murai, 399-8701, Matsumoto, Nagano, Japan aut Uhara Hisashi Department of Dermatology, Shinshu University School of Medicine, Asahi 3-1-1, 390-8621, Matsumoto, Nagano, Japan aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 194-197 1341-9625 20:1<194 2015 20 10147 https://doi.org/10.1007/s10147-014-0686-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0686-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Tokuda Yasutaka Division of Dermatology, Matsumoto Medical Center, Minami, 2-20-30, Murai, 399-8701, Matsumoto, Nagano, Japan aut NATIONALLICENCE 700 1- Arakura Fuyuko Division of Dermatology, Matsumoto Medical Center, Minami, 2-20-30, Murai, 399-8701, Matsumoto, Nagano, Japan aut NATIONALLICENCE 700 1- Uhara Hisashi Department of Dermatology, Shinshu University School of Medicine, Asahi 3-1-1, 390-8621, Matsumoto, Nagano, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 194-197 1341-9625 20:1<194 2015 20 10147